Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | San-Roman, B. (Beatriz) | |
dc.creator | Irache, J.M. (Juan Manuel) | |
dc.creator | Gomez, S. (Sara) | |
dc.creator | Tsapis, N. (Nicolás) | |
dc.creator | Gamazo, C. (Carlos) | |
dc.creator | Espuelas, S. (Socorro) | |
dc.date.accessioned | 2011-03-30T15:40:18Z | - |
dc.date.available | 2011-03-30T15:40:18Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | San Roman B, Irache JM, Gomez S, Tsapis N, Gamazo C, Espuelas MS. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. Eur J Pharm Biopharm 2008 Sep;70(1):98-108. | es_ES |
dc.identifier.issn | 0939-6411 | - |
dc.identifier.uri | https://hdl.handle.net/10171/17366 | - |
dc.description.abstract | It seems well established that CpG oligonucleotides Th1 biased adjuvant activity can be improved when closely associated with a variety of antigens in, for example, microparticles. In this context, we prepared 1-μm near non-charged PLGA 502 or PLGA 756 microparticles that loaded with high efficiency an antigen (50% ovalbumin (OVA), approximately) into their matrix and CpG-chitosan complexes (near to 20%) onto their surface maintaining OVA and CpG integrity intact. In the intradermal immunization studies, whereas OVA microencapsulated into PLGA 756 alone induced a strong humoral immune response assisted by a very clear Th1 bias (IgG2a/IgG1=0.875) that was decreased by CpG co-delivery (IgG2a/IgG1=0.55), the co-encapsulation of CpG with OVA in PLGA 502 particles significantly improved the antibody response and isotype shifting (IgG2a/IgG1=0.73) in comparison with mice immunized with OVA loaded PLGA 502 (IgG2a/IgG1=0). This improvement was not correlated with the cellular immune response where the effect of co-encapsulated CpG was rather negative (2030.2 pg/mL and 335.3 pg/mL IFN-g for OVA PLGA 502 for OVA CpG PLGA 502, respectively). These results underscore the critical role of polymer nature and microparticle characteristics to show the benefits of coencapsulating CpG motifs in close proximity with an antigen. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Microparticles | es_ES |
dc.subject | Antigen | es_ES |
dc.subject | Immunotherapy | es_ES |
dc.subject | CpG sequences | es_ES |
dc.subject | Th1/Th2 immune | es_ES |
dc.subject | Poly(lactic-co-glycolic) acid | es_ES |
dc.title | Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.